Growth Metrics

Novartis Ag (NVS) Depreciation & Amortization (CF) (2009 - 2018)

Novartis Ag recorded quarterly Depreciation & Amortization (CF) of $930.0 million in Q1 2018, up 101750447.05% quarter-over-quarter from $914.0 in Q4 2010.

Novartis Ag's Depreciation & Amortization (CF) history runs 3 years deep, the most recent figure standing at $930.0 million for Q1 2018.

  • In Q1 2018, Depreciation & Amortization (CF) changed N/A year-over-year to $930.0 million; the TTM figure through Dec 2018 stood at $930.0 million (changed N/A YoY), while the FY2009 annual figure was $2341.0, changed N/A from the prior year.
  • Depreciation & Amortization (CF) came in at $930.0 million for Q1 2018 at Novartis Ag, up from $914.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $930.0 million in Q1 2018 to a low of $930.0 million in Q1 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 509.00 Mn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 2.00 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 188.00 Mn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 581.00 Mn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 1.12 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 93.00 Mn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 1.61 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 594.00 Mn
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2018 930.00 Mn
Mar 31, 2018 930.00 Mn
Dec 31, 2010 914.00
Dec 31, 2010 914.00
Jun 30, 2010 665.00
Jun 30, 2010 665.00
Mar 31, 2010 761.00
Mar 31, 2010 761.00
Dec 31, 2009 629.00
Dec 31, 2009 629.00
Sep 30, 2009 614.00
Sep 30, 2009 614.00
Jun 30, 2009 550.00
Jun 30, 2009 550.00
Mar 31, 2009 548.00
Mar 31, 2009 548.00